# R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B

> **NCT01852435** · PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 648 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma Grade 3B

## Interventions

- **DRUG:** R-CEOP-70
- **DRUG:** R-CEOP-90
- **DRUG:** R-CHOP-50

## Key facts

- **NCT ID:** NCT01852435
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2017-12
- **Final completion:** 2018-02
- **Target enrollment:** 648 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852435, "R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01852435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*